{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T04:43:13Z","timestamp":1782276193981,"version":"3.54.5"},"reference-count":30,"publisher":"The Endocrine Society","issue":"4","license":[{"start":{"date-parts":[[2021,2,16]],"date-time":"2021-02-16T00:00:00Z","timestamp":1613433600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Context<\/jats:title>\n                  <jats:p>Although primary aldosteronism (PA) reduces quality of life (QOL), there have been no reports on whether treatment with a mineralocorticoid receptor antagonist (MRA) improves QOL in Japanese PA patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>Using the 36-Item Short-Form Health Survey (SF-36), we compared the QOL of PA patients before and after treatment and evaluated whether the effectiveness of MRAs differs by sex and serum potassium level.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>In 50 patients diagnosed with PA (with or without hypokalemia) and treated with an MRA, the SF-36 scores, blood pressure, and clinical features were assessed before, and 3 and 6 months after treatment. Separate analyses were also conducted for males and females.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The normative mean SF-36 score of the healthy subjects was 50. The pretreatment Role-Physical (RP) (46.7 \u00b1 1.8, P = .019), General Health (47.1 \u00b1 1.3, P = .042), and Role-Emotional (47.2 \u00b1 1.7, P = .045) SF-36 subscale scores of all PA patients were significantly lower than those of healthy subjects but were improved by MRA treatment. Females with PA had a lower RP score (45.1 \u00b1 2.2, P = .008), which was not improved by MRA treatment (46.1 \u00b1 2.4, P = .036). In addition, PA patients with hypokalemia had a lower Mental Health SF-36 subscale score (43.2 \u00b1 4.4, P = .041), which was improved by treatment with an MRA.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>MRAs improved the QOL of Japanese PA patients, but female PA patients may be more resistant to MRAs.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/jendso\/bvab020","type":"journal-article","created":{"date-parts":[[2021,2,16]],"date-time":"2021-02-16T17:43:36Z","timestamp":1613497416000},"source":"Crossref","is-referenced-by-count":10,"title":["Quality of Life of Primary Aldosteronism Patients by Mineralocorticoid Receptor Antagonists"],"prefix":"10.1210","volume":"5","author":[{"given":"Yuichi","family":"Yoshida","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Metabolism, Rheumatology and Nephrology, Faculty of Medicine, Oita University, Oita, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5100-3135","authenticated-orcid":false,"given":"Rika","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Oita University, Oita, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanako","family":"Shibuta","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Metabolism, Rheumatology and Nephrology, Faculty of Medicine, Oita University, Oita, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinori","family":"Ozeki","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Metabolism, Rheumatology and Nephrology, Faculty of Medicine, Oita University, Oita, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuhiro","family":"Okamoto","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Metabolism, Rheumatology and Nephrology, Faculty of Medicine, Oita University, Oita, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koro","family":"Gotoh","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Metabolism, Rheumatology and Nephrology, Faculty of Medicine, Oita University, Oita, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Masaki","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Metabolism, Rheumatology and Nephrology, Faculty of Medicine, Oita University, Oita, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6506-4820","authenticated-orcid":false,"given":"Hirotaka","family":"Shibata","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Metabolism, Rheumatology and Nephrology, Faculty of Medicine, Oita University, Oita, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2021,2,16]]},"reference":[{"issue":"11","key":"2021121113585111700_CIT0001","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1016\/j.jacc.2006.07.059","article-title":"A prospective study of the prevalence of primary aldosteronism in 1125 hypertensive patients","volume":"48","author":"Rossi","year":"2006","journal-title":"J Am Coll Cardiol."},{"issue":"3","key":"2021121113585111700_CIT0002","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1210\/jc.2003-031337","article-title":"Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents","volume":"89","author":"Mulatero","year":"2004","journal-title":"J Clin Endocrinol Metab."},{"issue":"5","key":"2021121113585111700_CIT0003","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1210\/jc.2015-4061","article-title":"The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline","volume":"101","author":"Funder","year":"2016","journal-title":"J Clin Endocrinol Metab."},{"issue":"3","key":"2021121113585111700_CIT0004","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1161\/HYPERTENSIONAHA.117.10263","article-title":"Prevalence of cardiovascular disease and its risk factors in primary aldosteronism: a Multicenter Study in Japan","volume":"71","author":"Ohno","year":"2018","journal-title":"Hypertension."},{"issue":"3","key":"2021121113585111700_CIT0005","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ando.2016.05.001","article-title":"SFE\/SFHTA\/AFCE primary aldosteronism consensus: introduction and handbook","volume":"77","author":"Amar","year":"2016","journal-title":"Ann Endocrinol (Paris)."},{"issue":"9","key":"2021121113585111700_CIT0006","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1038\/s41440-019-0284-9","article-title":"The Japanese Society of hypertension guidelines for the management of hypertension (JSH 2019)","volume":"42","author":"Umemura","year":"2019","journal-title":"Hypertens Res."},{"issue":"5","key":"2021121113585111700_CIT0007","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1159\/000093956","article-title":"Psychological aspects of primary aldosteronism","volume":"75","author":"Sonino","year":"2006","journal-title":"Psychother Psychosom."},{"issue":"3","key":"2021121113585111700_CIT0008","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1210\/jc.2009-1763","article-title":"Improved quality of life, blood pressure, and biochemical status following laparoscopic adrenalectomy for unilateral primary aldosteronism","volume":"95","author":"Sukor","year":"2010","journal-title":"J Clin Endocrinol Metab."},{"issue":"9","key":"2021121113585111700_CIT0009","doi-asserted-by":"crossref","first-page":"2904","DOI":"10.1210\/jc.2011-0138","article-title":"Quality of life in patients with bilateral primary aldosteronism before and during treatment with spironolactone and\/or amiloride, including a comparison with our previously published results in those with unilateral disease treated surgically","volume":"96","author":"Ahmed","year":"2011","journal-title":"J Clin Endocrinol Metab."},{"issue":"6","key":"2021121113585111700_CIT0010","doi-asserted-by":"crossref","first-page":"E878","DOI":"10.1210\/jc.2010-2723","article-title":"Psychological assessment of primary aldosteronism: a controlled study","volume":"96","author":"Sonino","year":"2011","journal-title":"J Clin Endocrinol Metab."},{"issue":"12","key":"2021121113585111700_CIT0011","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1016\/j.jpsychires.2012.08.025","article-title":"Quality of life in patients with primary aldosteronism: gender differences in untreated and long-term treated patients and associations with treatment and aldosterone","volume":"46","author":"K\u00fcnzel","year":"2012","journal-title":"J Psychiatr Res."},{"issue":"1","key":"2021121113585111700_CIT0012","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1210\/jc.2017-01442","article-title":"Quality of life in primary aldosteronism: a comparative effectiveness study of adrenalectomy and medical treatment","volume":"103","author":"Velema","year":"2018","journal-title":"J Clin Endocrinol Metab."},{"issue":"Suppl 1","key":"2021121113585111700_CIT0013","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s12893-018-0432-1","article-title":"Effect of unilateral adrenalectomy on the quality of life of patients with lateralized primary aldosteronism","volume":"18","author":"Citton","year":"2019","journal-title":"BMC Surg."},{"issue":"7","key":"2021121113585111700_CIT0014","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1111\/iju.14016","article-title":"Changes in quality of life after laparoscopic adrenalectomy for patients with primary aldosteronism: Prospective 2-year longitudinal cohort study in a Japanese tertiary center","volume":"26","author":"Ishidoya","year":"2019","journal-title":"Int J Urol."},{"issue":"11","key":"2021121113585111700_CIT0015","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/S0895-4356(98)00096-1","article-title":"Psychometric and clinical tests of validity of the Japanese SF-36 Health Survey","volume":"51","author":"Fukuhara","year":"1998","journal-title":"J Clin Epidemiol."},{"issue":"11","key":"2021121113585111700_CIT0016","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/S0895-4356(98)00095-X","article-title":"Translation, adaptation, and validation of the SF-36 Health Survey for use in Japan","volume":"51","author":"Fukuhara","year":"1998","journal-title":"J Clin Epidemiol."},{"issue":"12","key":"2021121113585111700_CIT0017","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.jclinepi.2009.01.022","article-title":"Estimating a preference-based index from the Japanese SF-36","volume":"62","author":"Brazier","year":"2009","journal-title":"J Clin Epidemiol."},{"issue":"1","key":"2021121113585111700_CIT0018","doi-asserted-by":"crossref","first-page":"26","DOI":"10.3109\/15622975.2012.665480","article-title":"Gender differences in anxiety and depressive symptoms in patients with primary hyperaldosteronism: a cross-sectional study","volume":"15","author":"Apostolopoulou","year":"2014","journal-title":"World J Biol Psychiatry."},{"issue":"1","key":"2021121113585111700_CIT0019","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.yhbeh.2008.02.004","article-title":"Chronic treatment with the mineralocorticoid hormone aldosterone results in increased anxiety-like behavior","volume":"54","author":"Hlavacova","year":"2008","journal-title":"Horm Behav."},{"issue":"5","key":"2021121113585111700_CIT0020","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1177\/0269881109106955","article-title":"Eplerenone, a selective mineralocorticoid receptor blocker, exerts anxiolytic effects accompanied by changes in stress hormone release","volume":"24","author":"Hlavacova","year":"2010","journal-title":"J Psychopharmacol."},{"issue":"1","key":"2021121113585111700_CIT0021","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1517\/14728222.8.1.7","article-title":"Angiotensin as a target for the treatment of Alzheimer\u2019s disease, anxiety and depression","volume":"8","author":"Gard","year":"2004","journal-title":"Expert Opin Ther Targets."},{"issue":"3","key":"2021121113585111700_CIT0022","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.regpep.2004.12.015","article-title":"Anti-stress and anti-anxiety effects of centrally acting angiotensin II AT1 receptor antagonists","volume":"128","author":"Saavedra","year":"2005","journal-title":"Regul Pept."},{"issue":"12","key":"2021121113585111700_CIT0023","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1055\/s-0043-121706","article-title":"Health-related quality of life and mental health in primary aldosteronism: a systematic review","volume":"49","author":"Velema","year":"2017","journal-title":"Horm Metab Res."},{"issue":"8","key":"2021121113585111700_CIT0024","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/jhh.2009.96","article-title":"Spironolactone reduces severity of obstructive sleep apnoea in patients with resistant hypertension: a preliminary report","volume":"24","author":"Gaddam","year":"2010","journal-title":"J Hum Hypertens."},{"key":"2021121113585111700_CIT0025","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1471-244X-3-15","article-title":"The renin-angiotensin-aldosterone system in patients with depression compared to controls\u2013a sleep endocrine study","volume":"3","author":"Murck","year":"2003","journal-title":"BMC Psychiatry."},{"issue":"1","key":"2021121113585111700_CIT0026","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1253\/circj.CJ-17-0323","article-title":"Double-blind, randomized, placebo-controlled trial evaluating the efficacy and safety of eplerenone in Japanese patients with chronic heart failure (J-EMPHASIS-HF)","volume":"82","author":"Tsutsui","year":"2017","journal-title":"Circ J."},{"issue":"1","key":"2021121113585111700_CIT0027","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1161\/HYPERTENSIONAHA.119.13569","article-title":"Double-blind randomized phase 3 study comparing esaxerenone (CS-3150) and eplerenone in patients with essential hypertension (ESAX-HTN Study)","volume":"75","author":"Ito","year":"2020","journal-title":"Hypertension."},{"issue":"1","key":"2021121113585111700_CIT0028","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S2213-8587(17)30367-4","article-title":"Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study","volume":"6","author":"Hundemer","year":"2018","journal-title":"Lancet Diabetes Endocrinol."},{"key":"2021121113585111700_CIT0029","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.ejphar.2015.06.015","article-title":"Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist","volume":"761","author":"Arai","year":"2015","journal-title":"Eur J Pharmacol."},{"issue":"5","key":"2021121113585111700_CIT0030","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1111\/j.1365-2265.2007.02775.x","article-title":"Primary aldosteronism: renaissance of a syndrome","volume":"66","author":"Young","year":"2007","journal-title":"Clin Endocrinol (Oxf)."}],"container-title":["Journal of the Endocrine Society"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jes\/advance-article-pdf\/doi\/10.1210\/jendso\/bvab020\/36283039\/bvab020.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jes\/article-pdf\/5\/4\/bvab020\/41725628\/bvab020.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jes\/article-pdf\/5\/4\/bvab020\/41725628\/bvab020.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,11]],"date-time":"2021-12-11T13:59:28Z","timestamp":1639231168000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jes\/article\/doi\/10.1210\/jendso\/bvab020\/6139137"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,16]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jendso\/bvab020","relation":{},"ISSN":["2472-1972"],"issn-type":[{"value":"2472-1972","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,4,1]]},"published":{"date-parts":[[2021,2,16]]},"article-number":"bvab020"}}